BeyondSpring IncBYSI
Price$0.81

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$6.7MTTM through 30 Jun 2026
Free Cash Flow -$16.7MTTM through 30 Jun 2026

Margins

Current

Returns

18.8%ROE
-54.8%ROA

Balance Sheet Health

Debt / Equity-1.41x
Current Ratio1.54x
Net Debt-$12.6Mnet cash position
Cash & Equivalents$2.7M

Quality Metrics

Altman Z-Score-41.32
Piotroski F-Score2 / 9

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $0
Diluted EPS
'14'15'20'21'22
FY2022: $-0.85

Dividend

No dividend

Capital Allocation

R&D Spend$4.6M

Segment Performance

SegmentRevenueYoYOutlook
Plinabulin pipeline$0
View details

Advancing the DUBLIN-4 confirmatory global Phase 3 study in EGFR wild-type NSCLC.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.